Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106872 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
A Phase 1 study of Sarcoma and Soft Tissue Sarcoma, sponsored by Mohammed M Milhem.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT01106872 is a Phase 1 study of Sarcoma and Soft Tissue Sarcoma that has completed, run by Mohammed M Milhem. The registered enrollment target is 47 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01106872, a Phase 1 study of Sarcoma and Soft Tissue Sarcoma, has completed, sponsored by Mohammed M Milhem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2010-09 |
| Est. Completion | 2017-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01106872
The ClinicalTrials.gov registry entry for NCT01106872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (95% lower). The listed sponsor is Mohammed M Milhem, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid is the first listed.
NCT01106872 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT01106872 about?
NCT01106872 is a clinical study titled "Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas". The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is inv...
What is the current status of trial NCT01106872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2010-09. Estimated completion is 2017-08-22.
What conditions does trial NCT01106872 study?
This clinical trial studies the following conditions: Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Locally Advanced Sarcoma, Unresectable Sarcoma.
What interventions are being tested in trial NCT01106872?
The interventions under investigation include: Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT01106872?
This trial is sponsored by Mohammed M Milhem, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01106872 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.